BioAgilytix Labs has named life sciences veteran Jim Datin as the new CEO of the outsourced laboratory services company.

In a career spanning more than 25 years, Datin has been a CEO, director, and executive in companies throughout the United States, Europe, and Asia. Datin’s appointment follows the June investment into Research Triangle Park-based BioAgilytix from Riverside Partners, a Boston private equity firm focused on health care and technology investing. The investment amount was not disclosed. Riverside says it invests in companies with revenue between $20 million and $200 million and earnings between $5 million and $25 million.

Datin was previously executive vice president and managing director at Safeguard Scientifics. He has also held posts at Dendrite International, GlaxoSmithKline and Baxter Healthcare.

BioAgilytix provides contract lab testing services for pharmaceutical, biotechnology and agriculture companies. The company specializes in large-molecule bioanalysis providing insight into the safety, efficacy, and mechanism of action of drug candidates throughout the clinical trial process.

BioAgilytix says it is a partner with six of the top 10 global pharmaceutical and biotech companies.